Insulet Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Insulet stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PODD, but not buy additional shares or sell existing shares.
View analyst ratings for Insulet or view top-rated stocks.

Wall Street analysts have given Insulet a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Insulet wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Monday, February, 22nd. The medical instruments supplier reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.22. The medical instruments supplier had revenue of $246.10 million for the quarter, compared to the consensus estimate of $232.89 million. Insulet had a net margin of 3.33% and a trailing twelve-month return on equity of 8.94%. The business's revenue was up 17.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 earnings per share.
View Insulet's earnings history.

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PODD shares have increased by 66.8% and is now trading at $287.13.
View which stocks have been most impacted by COVID-19.

Insulet updated its first quarter 2021 After-Hours earnings guidance on Tuesday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $245.52-253.44 million, compared to the consensus revenue estimate of $229.58 million.

17 equities research analysts have issued 12 month price targets for Insulet's shares. Their forecasts range from $179.00 to $320.00. On average, they anticipate Insulet's stock price to reach $254.24 in the next twelve months. This suggests that the stock has a possible downside of 11.5%.
View analysts' price targets for Insulet or view top-rated stocks among Wall Street analysts.

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), STERIS (STE) and Varian Medical Systems (VAR).
View all of PODD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.19%), State of Alaska Department of Revenue (0.03%) and First Hawaiian Bank (0.02%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet or view top insider-selling stocks.

PODD stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., and First Hawaiian Bank.
View insider buying and selling activity for Insulet or or view top insider-buying stocks.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $287.13.

Insulet has a market capitalization of $18.97 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis.

Insulet employs 1,900 workers across the globe.

Insulet was founded in 2000.

The official website for Insulet is www.insulet.com.

Insulet is headquartered at 100 NAGOG PARK, ACTON MA, 01720.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]